Related Experiment Videos
Salmeterol: a long-acting beta 2-agonist
1Division of Pulmonary and Critical Care Medicine, Temple University Health Sciences Center, Philadelphia, PA, USA.
The Journal of the American Osteopathic Association
|May 22, 1998
Summary
Salmeterol xinafoate, a long-acting beta 2-agonist, improves lung function and quality of life for chronic asthma patients. It is an effective add-on therapy when used correctly with corticosteroids, but not for rescue relief.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Clinical Therapeutics
Background:
- Chronic asthma management often requires combination therapy.
- Salmeterol xinafoate is a long-acting beta 2-adrenoreceptor agonist.
- Patients with persistent symptoms despite standard treatment may benefit from additional therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of salmeterol xinafoate in chronic asthma management.
- To assess its role in patients with symptomatic asthma inadequately controlled by inhaled corticosteroids and short-acting beta 2-agonists.
Main Methods:
- Inhaled administration of salmeterol xinafoate twice daily.
- Assessment of lung function, asthma exacerbations, and quality of life.
- Evaluation in patients with symptomatic asthma despite concurrent therapies.
Main Results:
- Improved lung function and reduced acute asthmatic exacerbations.
- Enhanced patient quality of life, including daytime and nighttime symptom scores.
- Sustained benefits observed despite potential for tolerance to bronchoprotective effects.
Conclusions:
- Salmeterol xinafoate is an effective and safe adjunctive therapy for chronic asthma in adolescents and adults.
- Proper patient education on use with corticosteroids and avoidance of rescue use is crucial.
- It offers significant benefits for patients with persistent symptoms.